Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 19/20 | 0.82 |
| ▸ | CCNT1 | O60563 | 16/20 | 0.82 |
| ▸ | CDK2 | P24941 | 7/20 | 0.82 |
| ▸ | CDK1 | P06493 | 3/20 | 0.82 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.82 |
| ▸ | ABL2 | P42684 | 3/20 | 0.82 |
| ▸ | GSK3A | P49840 | 3/20 | 0.82 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.82 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.82 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.82 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.82 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.82 |
| ▸ | CDK4 | P11802 | 2/20 | 0.82 |
| ▸ | CCND1 | P24385 | 2/20 | 0.82 |
| ▸ | CDK7 | P50613 | 2/20 | 0.82 |
| ▸ | CCNH | P51946 | 2/20 | 0.82 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.82 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.72 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.72 |
| ▸ | CCNK | O75909 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486339 | 0.90 | CDK9 (1.00) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL4430368 | 0.90 | CDK9 (1.00) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL4427553 | 0.87 | CDK9 (0.85) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL2030393 | 0.86 | CDK9 (0.63) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL4435897 | 0.86 | CCNT1 (0.69) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL12487288 | 0.85 | CDK9 (0.67) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL2462111 | 0.84 | CDK2 (1.00) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL4430596 | 0.83 | CCNT1 (0.83) | CDK9CCNT1CDK2CDK1CCNB1 | |
| SCHEMBL8515451 | 0.83 | CCNT1 (0.82) | CDK9CCNT1CDK2CDK1CCNB1 | |
| Hydrochloric Acid SCHEMBL2462522 | 0.83 | CDK2 (0.98) | CDK9CCNT1CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-19 | — | — | US | claimed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | claimed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | claimed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | claimed |
| EP-2137166-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | claimed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | claimed |
| WO-2020235672-A1 | PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE | 国立大学法人京都大学 (JP) | 2020-11-26 | — | — | WO | disclosed |
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2137166-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK2, CDK6, CDK5 | CDK9 8/4885CCNT1 45/4885CDK2 1/4885 |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK6, CDK2, CDK1 | CDK9 7/4885CCNT1 45/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.